NO954091L - 1,5-Benzodinazine derivatives with CCK and / or gastrin antagonistic activity - Google Patents

1,5-Benzodinazine derivatives with CCK and / or gastrin antagonistic activity

Info

Publication number
NO954091L
NO954091L NO954091A NO954091A NO954091L NO 954091 L NO954091 L NO 954091L NO 954091 A NO954091 A NO 954091A NO 954091 A NO954091 A NO 954091A NO 954091 L NO954091 L NO 954091L
Authority
NO
Norway
Prior art keywords
hydrogen
cck
calkyl
alkyl
benzodinazine
Prior art date
Application number
NO954091A
Other languages
Norwegian (no)
Other versions
NO954091D0 (en
Inventor
Harry Finch
Pritom Shah
Robin Arthur Ellis Carr
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939307833A external-priority patent/GB9307833D0/en
Priority claimed from GB9406037A external-priority patent/GB9406037D0/en
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of NO954091D0 publication Critical patent/NO954091D0/en
Publication of NO954091L publication Critical patent/NO954091L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med den generelle formel (I) og deres fysio-logisk akseptable salter hvor gruppen NRRer en 5 til 7-leddet mettet heterocyklisk ring som kan være substituert med én eller to metylgrupper; Rer Calkyl, C.cykloalkyl eller : fenyl, eventuelt substituert med 1 eller 2 halogenatomer; R» er fenyl eller fenyl substituert med én eller to grupper valgt fra halogen, Calkyl, trifluormetyl, trifluormetoksy eller (CH)Rhvor n er null eller 1, og Rer Calkoksy, hydroksy, nitro, cyano, C0R, S(0)pCH, NRR, CONRR, S0NRCO(C.alkyl), tetrazolyl, karboksamidotetrazolyl, eller 3-trifluormetyl-. ! 1,2,4-triazolyl; Rer hydrogen, C.alkyl eller benzyl; Rer j hydrogen eller Calkyl, Rer hydrogen, Calkyl, S0CHeller S0CF, X er hydrogen, C-alkyl eller halogen; m er null, 1 \ eller, og p er null, 1 eller 2; fremgangsmåter for deres i fremstilling og deres medisinske anvendelse som antagonister ! for gastrin og CCK.Compounds of general formula (I) and their physiologically acceptable salts wherein the group NRR is a 5 to 7 membered saturated heterocyclic ring which may be substituted by one or two methyl groups; R is Calkyl, C 1-8 cycloalkyl or: phenyl, optionally substituted by 1 or 2 halogen atoms; R NRR, CONRR, SONRCO (C 1-4 alkyl), tetrazolyl, carboxamidotetrazolyl, or 3-trifluoromethyl-. ! 1,2,4-triazolyl; R is hydrogen, C 1-4 alkyl or benzyl; R is j hydrogen or Calkyl, R is hydrogen, Calkyl, SOCH or SOCF, X is hydrogen, C-alkyl or halogen; m is zero, 1 \ or, and p is zero, 1 or 2; procedures for their preparation and their medicinal use as antagonists! for gastrin and CCK.

NO954091A 1993-04-15 1995-10-13 1,5-Benzodinazine derivatives with CCK and / or gastrin antagonistic activity NO954091L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin
GB9406037A GB9406037D0 (en) 1994-03-29 1994-03-29 1,5 Benzodiazepine derivatives
PCT/EP1994/001130 WO1994024151A1 (en) 1993-04-15 1994-04-13 1,5 benzodiazepine derivatives having cck and/or gastrin antagonistic activity

Publications (2)

Publication Number Publication Date
NO954091D0 NO954091D0 (en) 1995-10-13
NO954091L true NO954091L (en) 1995-12-13

Family

ID=26302765

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954091A NO954091L (en) 1993-04-15 1995-10-13 1,5-Benzodinazine derivatives with CCK and / or gastrin antagonistic activity

Country Status (14)

Country Link
EP (1) EP0694040A1 (en)
JP (1) JPH08508743A (en)
CN (1) CN1120845A (en)
AU (1) AU688316B2 (en)
CA (1) CA2158972A1 (en)
CZ (1) CZ267695A3 (en)
FI (1) FI954852A (en)
HU (1) HUT74091A (en)
NO (1) NO954091L (en)
NZ (1) NZ265271A (en)
OA (1) OA10236A (en)
PL (1) PL311083A1 (en)
SK (1) SK125495A3 (en)
WO (1) WO1994024151A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430068T2 (en) * 1993-12-28 2002-08-14 Shionogi & Co benzodiazepine derivatives
US6239131B1 (en) * 1996-12-10 2001-05-29 Zeria Pharmaceutical Co., Ltd. 1,5 Benzodiazepine derivatives
US6444849B1 (en) 1997-06-25 2002-09-03 Mitsubishi Chemical Corporation Amide derivatives
JP2000026434A (en) 1998-06-05 2000-01-25 Zeria Pharmaceut Co Ltd New 1,5-benzodiazepine derivative
EP1142868A4 (en) * 1998-12-22 2004-09-29 Mitsubishi Chem Corp Amide derivatives
GB201414116D0 (en) 2014-08-08 2014-09-24 Trio Medicines Ltd Benzodiazepine derivatives
GB201513979D0 (en) 2015-08-07 2015-09-23 Trio Medicines Ltd Synthesis of benzodiazepine derivatives
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (en) * 1988-12-29 1994-01-21 Roussel Uclaf NOVEL 2,4-DIOXO 2,3,4,5-TETRAHYDRO 1H-1,5-BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS
FR2659653B1 (en) * 1990-03-13 1992-05-22 Rhone Poulenc Sante DERIVATIVES OF UREA, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
OA10236A (en) 1997-10-07
FI954852A0 (en) 1995-10-12
NZ265271A (en) 1997-06-24
AU6567594A (en) 1994-11-08
SK125495A3 (en) 1996-06-05
CA2158972A1 (en) 1994-10-27
NO954091D0 (en) 1995-10-13
CZ267695A3 (en) 1996-04-17
WO1994024151A1 (en) 1994-10-27
JPH08508743A (en) 1996-09-17
AU688316B2 (en) 1998-03-12
HUT74091A (en) 1996-11-28
HU9502977D0 (en) 1995-12-28
CN1120845A (en) 1996-04-17
EP0694040A1 (en) 1996-01-31
PL311083A1 (en) 1996-02-05
FI954852A (en) 1995-10-12

Similar Documents

Publication Publication Date Title
ES8801651A1 (en) Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents.
ATE139233T1 (en) ANNELATED THIOPHENE DERIVATIVES, THEIR PREPARATION AND USE
ES2125294T3 (en) IMIDAZO (1,2-A) PIRIDINES AS BRADIQUININE ANTAGONISTS.
NO955074L (en) 1-substituted istain and oxindole derivatives as inhibitors of acetylcholinesterase
ATE116303T1 (en) ARYL-HETEROARYL-CARBINOL DERIVATIVES WITH ANALGESIC ACTIVITY.
ATE2674T1 (en) SUBSTITUTED 3-ALKYL-6-PHENYL-1,2,4-TRIAZOLO(4,3-A)PYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK87182A (en) PROCEDURE FOR PREPARING IMIDAZODIAZEPINS OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS
NO954091L (en) 1,5-Benzodinazine derivatives with CCK and / or gastrin antagonistic activity
DK225081A (en) AMINOPROPIOPHENON DERIVATIVES AND THEIR ACID ADDITIONAL SALT PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS GUNGICIDES
FI964463A (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
PT74563A (en) Process for preparing benzamide derivatives and pharmaceutical compositions containing the same
DK118083D0 (en) THEOPHYLLINYLALKYLOXADIAZOLES OR ADDITIONAL SALTS THEREOF, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS
ES2175405T3 (en) ADENOSINE DERIVATIVES
ES2077354T3 (en) 2-HYDROXY-2-PHENYLETHYLAMINE DERIVATIVES USEFUL AS BETA-3-ADRENOCEPTOR AGONISTS.
DE68921719D1 (en) Amphotericin B derivatives.
ES488901A1 (en) Derivatives of substituted 2-benzoyl glycinanilides, their preparation and their use in anxiolytic medicaments.
NO20006350L (en) Derivatives of 3- (2-oxo- [1,3 '] bipyrrolidinyl-3-ylidene methyl) cephemer
NO167286C (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZOTIAZEPINE DERIVATIVES.
NO923507L (en) HETEROPOLYCYCLIC, BIOCIDE COMPOUNDS AND THEIR USE IN MEDICINE
NO883263D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZIMIDAZOLE DERIVATIVES.
DK160271C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF 5-HALOGENVINYL-URACIL DERIVATIVES
NO922812L (en) NAFTYRIDINE AND QUINOLIZINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
TH20764B (en) Heterocyclic derivatives of azylone
TH20764A (en) Heterocyclic derivatives of azylone